HighGravityDataHumana — Nov 5, 2025 release
Fiscal 2025 third-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000049071-25-000055
Showing in the filing
Adjusted FY 2025 EPS
“approximately $17.00”
Period
FY2025
Measure
Company-defined measure
Source
Prose
All guidance in this release · 25
GAAP EPS for FY2025
“approximately $12.26”
Insurance segment benefit ratio for FY2025
“90.1 percent to 90.5 percent”
Individual Medicare Advantage membership (de… for FY2025
“approximately 425,000 members”
Adjusted FY 2025 EPS for FY2025
“approximately $17.00”
Diluted earnings per share (EPS) - Adjusted … for FY2025
“approximately $17.00”
Diluted EPS - Non-GAAP for FY2025
“approximately $17.00”
Diluted EPS - GAAP for FY2025
“approximately $12.26”
Diluted earnings per share (EPS) - GAAP for FY2025
“approximately $12.26”
Total Revenues Consolidated - GAAP for FY2025
“at least $128 billion”
Total Revenues Insurance segment - GAAP for FY2025
“at least $123 billion”
Total Revenues CenterWell segment - GAAP for FY2025
“at least $21.5 billion”
Change in year-end medical membership - Indi… for FY2025
“Decline of approximately 425,000”
Change in year-end medical membership - Grou… for FY2025
“Relatively flat”
Change in year-end medical membership - Medi… for FY2025
“Growth of approximately 200,000”
Change in year-end medical membership - Stat… for FY2025
“Growth of approximately 160,000”
Operating Cost Ratio - Consolidated GAAP for FY2025
“11.6% to 12.1%”
Operating Cost Ratio - Consolidated Non-GAAP for FY2025
“11.3% to 11.7%”
Insurance segment income from operations - G… for FY2025
“$1.6 billion to $2.0 billion”
CenterWell segment income from operations - … for FY2025
“$1.1 billion to $1.5 billion”
CenterWell segment income from operations - … for FY2025
“$1.3 billion to $1.7 billion”
Effective Tax Rate - GAAP for FY2025
“approximately 20.0%”
Effective Tax Rate - Non-GAAP for FY2025
“approximately 25.0%”
Weighted Avg. Share Count for Diluted EPS for FY2025
“approximately 121 million”
Cash flows from operations - GAAP for FY2025
“$2.4 billion to $2.9 billion”
Capital expenditures for FY2025
“approximately $650 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
“ We feel positive about the direction we’re headed and the value we are creating for our members, patients and investors. ” FY 2025 Earnings Guidance Humana revises its GAAP EPS guidance for the year ending December 31, 2025 (FY 2025) to 'approximately $12.26' from 'approximately $13.77', while affirming its Adjusted EPS guidance of 'approximately $17.00'. Additional FY 2025 guidance points are included on page 14 of this earnings release. 2 Diluted earnings per share FY 2025 Guidance FY 2024 (a) GAAP approximately $12.26 $9.98 Amortization associated with identifiable intangibles 0.42 0.50 Put/call valuation adjustments associated with the company's non-consolidating minority interest investments (b) 3.81 2.45 Value creation initiatives (b) 2.65 2.33 Impact of exit of employer group commercial medical products business (b) (0.52) 1.19 Settlement of certain litigation expenses (b) 0.13 — Loss on sale of business (b) 0.52 — Impairment charges (b) 0.27 1.65 Cumulative net tax impact (2.54) (1.89) Adjusted (non-GAAP) – FY 2025 projected (b); FY 2024 reported approximately $17.00 $16.21 Refer to the "Footnotes" section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well as reconciliations. Humana Consolidated Highlights Humana Inc. Summary of Results ($ in millions, except per share amounts) 3Q25 (a) 3Q24 (a) YTD 2025 (a) YTD 2024 (a) Revenues $32,649 $29,397 $97,149 $88,548 Revenues - Adjusted (non-GAAP) $32,649 $29,300 $97,149 $88,011 Pretax results $134 $6
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.